Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a life-science filing stuffed with patent jargon and R&D tables can stall any analysis. 10x Genomics’ disclosures are no exception—its single-cell and spatial biology business drives complex revenue recognition rules, consumable pull-through metrics, and ongoing IP litigation that run deep in every report. Stop searching line-by-line and start seeing answers.
Stock Titan’s platform ingests each new document the moment it hits EDGAR and delivers AI-powered summaries that make sense of every form—whether you’re comparing instrument placements in the latest 10x Genomics quarterly earnings report 10-Q filing or reviewing risk-factor updates in an 8-K material events explained. Want real-time alerts on 10x Genomics Form 4 insider transactions? Our dashboard flags executive stock sales or option exercises seconds after they post, so you can monitor 10x Genomics insider trading Form 4 transactions without refreshing EDGAR.
Inside the same workspace you’ll also find:
- 10x Genomics annual report 10-K simplified—AI highlights R&D spend, consumable margins, and pending lawsuits.
- 10x Genomics proxy statement executive compensation—quick tables summarizing pay, grants, and voting items.
- Concise charts for revenue trends, segment mix, and cash burn drawn from every filing.
Q1 FY25 (Apr–Jun 2025, J-GAAP) snapshot:
- Ordinary income ¥2.13 tn, –10.5 % YoY on softer trading and loan yields.
- Ordinary profit ¥368.6 bn, +4.0 % YoY; net profit attributable to owners ¥290.5 bn, +0.4 % (EPS ¥115.90).
- Total assets fell 1.6 % since Mar-25 to ¥278.7 tn; own-capital ratio edged up to 3.7 %.
- NPL ratio improved to 0.73 % (–23 bp); credit-related costs a modest ¥11.4 bn.
Guidance & shareholder returns: Full-year profit target lifted 8.5 % to ¥1.02 tn (15 % YoY growth), implying FY EPS ¥407.81. Dividend outlook unchanged at ¥145/share (up ¥5 YoY) with ¥72.5 interim.
Segment colour: Retail & Business Banking and CIBC drove net business profit growth; Global Markets cooled as ETF-related gains shrank to ¥3.2 bn (vs ¥31.7 bn). Net interest income rose 30 % YoY while trading income slid 14 %.
Balance-sheet trends: Loans down ¥0.14 tn to ¥94.0 tn; deposits down ¥0.62 tn to ¥154.3 tn. Unrealised gains on securities up ¥162 bn to ¥1.37 tn, aided by equity market strength. Treasury stock grew to 14.4 m shares.
Takeaway: Upgraded guidance, better asset quality and stable dividends offset revenue pressure and a still-thin capital base, signalling cautious but improving fundamentals.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
What is the primary focus of 10X Genomics, Inc.?
How do 10X Genomics' solutions benefit researchers?
What makes 10X Genomics' technology stand out in the market?
Who are the typical customers of 10X Genomics?
In which research areas are 10X Genomics' products widely used?
How does 10X Genomics ensure data quality and reproducibility?
What role does innovation play in the company’s strategy?
How does 10X Genomics support democratization of advanced research tools?
